Health Canada has allowed the firm to bypass a requirement that tests be authorized for non-professional use prior to self-test authorization.

Investigators compared risk prediction using PathomIQ's platform to molecular test results, evaluating its ability to predict biochemical recurrence in high-risk patients.

Last week, readers were most interested in a story about Diasorin's submission to FDA for its POC testing instrument.

The Tulane team has developed a handful of other assays for TB detection, including a mass spec test for paucibacillary TB ...

Broader macroeconomic uncertainty has resulted in continued cautiousness for both investors and acquirers in the in vitro ...

NEW YORK – With the recent completion of a multisite study in Europe and the opening of a lab in Tennessee, Glasgow, Scotland-based liquid biopsy developer Dxcover plans to launch its infrared ...

A lab owner, marketing firm owner, and doctor have been sentenced to between 13 months and five years in prison for their roles in a multimillion-dollar lab fraud scheme.

Lund, Sweden-based Qlucore aims to have bladder cancer and AML tests available for clinical use in Europe by 2027.

NEW YORK – After months of declining share prices, diagnostics firm got a reprieve in June as the 360 Top 30 rose nearly 6 percent month over month. The Top 30 mirrored the broader markets as the Dow ...

NEW YORK – A federal judge on Tuesday ruled that the US Department of Health and Human Services' March decision to lay off 10,000 staff members as part of a major restructuring was likely unlawful and ...